Efficacy of Different Nitric Oxide-based Strategies in Preventing Experimental Cerebral Malaria by Plasmodium Berghei ANKA

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Feb 21

PMID 22348145

Citations 19

Authors

Yuri C Martins

Graziela M Zanini

John A Frangos

Leonardo J M Carvalho

Affiliations

Soon will be listed here.

Abstract

Background: Low nitric oxide (NO) bioavailability plays a role in the pathogenesis of human as well as of experimental cerebral malaria (ECM) caused by Plasmodium berghei ANKA (PbA). ECM is partially prevented by administration of the NO-donor dipropylenetriamine NONOate (DPTA-NO) at high concentration (1 mg/mouse), which also induces major side effects such as a sharp drop in blood pressure. We asked whether alternative strategies to improve NO bioavailability with minor side effects would also be effective in preventing ECM.

Methodology/principal Findings: Mice were infected with PbA and prophylactically treated twice a day with bolus injections of L-arginine, Nω-hydroxy-nor-Arginine (nor-NOHA), tetrahydrobiopterin (BH4), separately or combined, sodium nitrite, sildenafil or sildenafil plus DPTA-NO starting on day 0 of infection. L-arginine and BH4 supplementation, with or without arginase inhibition by nor-NOHA, increased plasma nitrite levels but failed to protect against ECM development. Accordingly, prophylactic treatment with continuous delivery of L-arginine using osmotic pumps also did not improve survival. Similar outcomes were observed with sodium nitrite sildenafil (aimed at inhibiting phosphodiesterase-5) or with DPTA-NO. However, sildenafil (0.1 mg/mouse) in combination with a lower dose (0.1 mg/mouse) of DPTA-NO decreased ECM incidence (82 ± 7.4% mortality in the saline group and 38 ± 10.6% in the treated group; p<0.05). The combined prophylactic therapy did not aggravate anemia, had delayed effects in systolic, diastolic and mean arterial blood pressure and induced lower effects in pulse pressure when compared to DPTA-NO 1 mg/mouse.

Conclusions/significance: These data show that sildenafil lowers the amount of NO-donor needed to prevent ECM, resulting also in lesser side effects. Prophylactic L-arginine when given in bolus or continuous delivery and bolus BH4 supplementation, with or without arginase inhibition, were able to increase NO bioavailability in PbA-infected mice but failed to decrease ECM incidence in the doses and protocol used.

Citing Articles

Pathogenetic mechanisms and treatment targets in cerebral malaria.

Hadjilaou A, Brandi J, Riehn M, Friese M, Jacobs T Nat Rev Neurol. 2023; 19(11):688-709.

PMID: 37857843 DOI: 10.1038/s41582-023-00881-4.

Oxidative Stress in Malaria: Potential Benefits of Antioxidant Therapy.

Gomes A, Cunha N, Varela E, Brigido H, Vale V, Dolabela M Int J Mol Sci. 2022; 23(11).

PMID: 35682626 PMC: 9180384. DOI: 10.3390/ijms23115949.

Dexamethasone increased the survival rate in Plasmodium berghei-infected mice.

Moreira D, Uberti A, Gomes A, Ferreira M, da Silva Barbosa A, Varela E Sci Rep. 2021; 11(1):2623.

PMID: 33514836 PMC: 7846581. DOI: 10.1038/s41598-021-82032-7.

Elimination of Hepatic Rodent Parasites by Amino Acid Supplementation.

Meireles P, Bras D, Fontinha D, Chora A, Serre K, Mendes A iScience. 2020; 23(12):101781.

PMID: 33294789 PMC: 7689548. DOI: 10.1016/j.isci.2020.101781.

Citrulline protects mice from experimental cerebral malaria by ameliorating hypoargininemia, urea cycle changes and vascular leak.

Gramaglia I, Velez J, Chang Y, Caparros-Wanderley W, Combes V, Grau G PLoS One. 2019; 14(3):e0213428.

PMID: 30849122 PMC: 6407779. DOI: 10.1371/journal.pone.0213428.

References

White N, Turner G, Medana I, Dondorp A, Day N . The murine cerebral malaria phenomenon. Trends Parasitol. 2009; 26(1):11-5. PMC: 2807032. DOI: 10.1016/j.pt.2009.10.007. View

Reiter C, Wang X, Tanus-Santos J, Hogg N, Cannon 3rd R, Schechter A . Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002; 8(12):1383-9. DOI: 10.1038/nm1202-799. View

Boivin M . Effects of early cerebral malaria on cognitive ability in Senegalese children. J Dev Behav Pediatr. 2002; 23(5):353-64. DOI: 10.1097/00004703-200210000-00010. View

Pluta R, Dejam A, Grimes G, Gladwin M, Oldfield E . Nitrite infusions to prevent delayed cerebral vasospasm in a primate model of subarachnoid hemorrhage. JAMA. 2005; 293(12):1477-84. DOI: 10.1001/jama.293.12.1477. View

Shinozaki K, Nishio Y, Okamura T, Yoshida Y, Maegawa H, Kojima H . Oral administration of tetrahydrobiopterin prevents endothelial dysfunction and vascular oxidative stress in the aortas of insulin-resistant rats. Circ Res. 2000; 87(7):566-73. DOI: 10.1161/01.res.87.7.566. View

Hattori Y, Hattori S, Wang X, Satoh H, Nakanishi N, Kasai K . Oral administration of tetrahydrobiopterin slows the progression of atherosclerosis in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol. 2007; 27(4):865-70. DOI: 10.1161/01.ATV.0000258946.55438.0e. View

Campistron G, GUIRAUD R, Cros J, Mosser J . Pharmacokinetics of arginine and aspartic acid administered simultaneously in the rat: I. Plasma kinetics. Eur J Drug Metab Pharmacokinet. 1982; 7(4):307-13. DOI: 10.1007/BF03189634. View

Dondorp A, Nosten F, Stepniewska K, Day N, White N . Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005; 366(9487):717-25. DOI: 10.1016/S0140-6736(05)67176-0. View

Riley E, Couper K, Helmby H, Hafalla J, de Souza J, Langhorne J . Neuropathogenesis of human and murine malaria. Trends Parasitol. 2010; 26(6):277-8. DOI: 10.1016/j.pt.2010.03.002. View

10.

Zhang L, Zhang R, Wang Y, Zhang C, Zhang Z, Meng H . Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke. 2005; 36(4):847-52. DOI: 10.1161/01.STR.0000158923.19956.73. View

11.

Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, Helbok R . Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol. 2006; 32(2):177-88. DOI: 10.1111/j.1365-2990.2006.00706.x. View

12.

Lue T . Erectile dysfunction. N Engl J Med. 2000; 342(24):1802-13. DOI: 10.1056/NEJM200006153422407. View

13.

Astrand A, Bohlooly-Y M, Larsdotter S, Mahlapuu M, Andersen H, Tornell J . Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity. Am J Physiol Regul Integr Comp Physiol. 2004; 287(4):R749-58. DOI: 10.1152/ajpregu.00134.2004. View

14.

Renia L, Gruner A, Snounou G . Cerebral malaria: in praise of epistemes. Trends Parasitol. 2010; 26(6):275-7. DOI: 10.1016/j.pt.2010.03.005. View

15.

Yeo T, Lampah D, Gitawati R, Tjitra E, Kenangalem E, McNeil Y . Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis. 2008; 198(4):602-8. PMC: 2709993. DOI: 10.1086/590209. View

16.

Doyle M, Hoekstra J . Oxidation of nitrogen oxides by bound dioxygen in hemoproteins. J Inorg Biochem. 1981; 14(4):351-8. DOI: 10.1016/s0162-0134(00)80291-3. View

17.

Verhaar M, Westerweel P, van Zonneveld A, Rabelink T . Free radical production by dysfunctional eNOS. Heart. 2004; 90(5):494-5. PMC: 1768213. DOI: 10.1136/hrt.2003.029405. View

18.

Yeo T, Lampah D, Tjitra E, Gitawati R, Darcy C, Jones C . Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog. 2010; 6(4):e1000868. PMC: 2858698. DOI: 10.1371/journal.ppat.1000868. View

19.

Crabtree M, Channon K . Synthesis and recycling of tetrahydrobiopterin in endothelial function and vascular disease. Nitric Oxide. 2011; 25(2):81-8. PMC: 5357050. DOI: 10.1016/j.niox.2011.04.004. View

20.

Bratt J, Franzi L, Linderholm A, ORoark E, Kenyon N, Last J . Arginase inhibition in airways from normal and nitric oxide synthase 2-knockout mice exposed to ovalbumin. Toxicol Appl Pharmacol. 2009; 242(1):1-8. PMC: 3221650. DOI: 10.1016/j.taap.2009.09.018. View